Abstract: . . .  systemic 0.5% 0.4% No (0.62) Pulmonary 0.1% 0.5% No (0.16) Haemorrhage 4.7% 3.4% No Primary intracerebral 1.1% 1.3% No (0.73) Subdural or subarachnoid 0.8% 0.8% No (0.68) Non-central nervous system 7.7% 6.9% No (0.44) Severe adverse effects of drugs (other than anticoagulants) 0.8% 4.5% Yes Torsade de pointes 0.2% 0.8% Yes (0.007) Resuscitated cardiac arrest due to bradycardia or pulseless electrical activity < 0.1% 0.6% Yes (0.01) Pulmonary events 1.7% 7.3% Yes (< 0.001) Gastrointestinal events 2.1% 8.0% Yes (< 0.001) Bradycardia 4.2% 6.0% Yes (0.001) Prolongation of corrected QT interval (> 520 ms) 0.3% 1.9% Yes (< 0.001) Other adverse events 14.0% 25.4% Yes (< 0.001) * All-cause mortality for the AFFIRM trial, 3 and a composite primary endpoint which included heart failure, thromboembolism, bleeding, need for pacemaker implantation, death from cardiovascular causes, and other severe adverse effects of drugs for the Dutch trial. 4 Prompting discontinuation of a drug.  . . .
--2658,1,1329,1494,13291